Optimizing oncolytic virotherapy in cancer treatment

被引：419

作者：

Harrington, Kevin ^{[1
]}

Freeman, Daniel J. ^{[2
]}

Kelly, Beth ^{[2
]}

Harper, James ^{[3
]}

Soria, Jean-Charles ^{[2
,4
]}

机构：

[1] Inst Canc Res, Div Radiotherapy & Imaging, London, England

[2] AstraZeneca, Oncol R&D, Gaithersburg, MD USA

[3] AstraZeneca, Oncol R&D, Cambridge, England

[4] Univ Paris Sud, Dept Med & Med Oncol, Orsay, France

来源：

NATURE REVIEWS DRUG DISCOVERY | 2019年 / 18卷 / 09期

关键词：

HERPES-SIMPLEX-VIRUS; IMMUNE-CHECKPOINT BLOCKADE; ISOLATED LIMB PERFUSION; LAHERPAREPVEC T-VEC; VACCINIA VIRUS; TALIMOGENE LAHERPAREPVEC; PD-1; BLOCKADE; INTRAVENOUS DELIVERY; ACQUIRED-RESISTANCE; MEDIATED DELIVERY;

D O I：

10.1038/s41573-019-0029-0

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 [微生物学]; 090105 [作物生产系统与生态工程];

摘要：

In the wake of the success of modern immunotherapy, oncolytic viruses (OVs) are currently seen as a potential therapeutic option for patients with cancer who do not respond or fail to achieve durable responses following treatment with immune checkpoint inhibitors. OVs offer a multifaceted therapeutic platform because they preferentially replicate in tumour cells, can be engineered to express transgenes that augment their cytotoxic and immunostimulatory activities, and modulate the tumour microenvironment to optimize immune-mediated tumour eradication, both at locoregional and systemic sites of disease. Lysis of tumour cells releases tumour-specific antigens that trigger both the innate and adaptive immune systems. OVs also represent attractive combination partners with other systemically delivered agents by virtue of their highly favourable safety profiles. Rational combinations of OVs with different immune modifiers and/or antitumour agents, based on mechanisms of tumour resistance to immune-mediated attack, may benefit the large, currently underserved, population of patients who respond poorly to immune checkpoint inhibition.

引用

页码：689 / 706

页数：18

共 217 条

[41]

Effect of decorin on overcoming the extracellular matrix barrier for oncolytic virotherapy [J].

Choi, I-K ;

Lee, Y-S ;

Yoo, J. Y. ;

Yoon, A-R ;

Kim, H. ;

Kim, D-S ;

Seidler, D. G. ;

Kim, J-H ;

Yun, C-O .

GENE THERAPY, 2010, 17 (02) :190-201

[42]

Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect [J].

Choi, K-J ;

Kim, J-H ;

Lee, Y-S ;

Kim, J. ;

Suh, B-S ;

Kim, H. ;

Cho, S. ;

Sohn, J-H ;

Kim, G. E. ;

Yun, C-O .

GENE THERAPY, 2006, 13 (13) :1010-1020

[43]

Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade [J].

Chon, Hong Jae ;

Lee, Won Suk ;

Yang, Hannah ;

Kong, So Jung ;

Lee, Na Keum ;

Moon, Eun Sang ;

Choi, Jiwon ;

Han, Eun Chun ;

Kim, Joo Hoon ;

Ahn, Joong Bae ;

Kim, Joo Hang ;

Kim, Chan .

CLINICAL CANCER RESEARCH, 2019, 25 (05) :1612-1623

[44]

Durable complete responses in some recurrent highgrade glioma patients treated with Toca 511+Toca FC [J].

Cloughesy, Timothy F. ;

Landolfi, Joseph ;

Vogelbaum, Michael A. ;

Ostertag, Derek ;

Elder, James B. ;

Bloomfield, Stephen ;

Carter, Bob ;

Chen, Clark C. ;

Kalkanis, Steven N. ;

Kesari, Santosh ;

Lai, Albert ;

Lee, Ian Y. ;

Liau, Linda M. ;

Mikkelsen, Tom ;

Nghiemphu, Phioanh ;

Piccioni, David ;

Accomando, William ;

Diago, Oscar R. ;

Hogan, Daniel J. ;

Gammon, Dawn ;

Kasahara, Noriyuki ;

Kheoh, Thian ;

Jolly, Douglas J. ;

Gruber, Harry E. ;

Das, Asha ;

Walbert, Tobias .

NEURO-ONCOLOGY, 2018, 20 (10) :1383-1392

[45]

Molecular Pathways: Targeting the Stimulator of InterferonGenes(STING) in the Immunotherapyof Cancer [J].

Corrales, Leticia ;

Gajewski, Thomas F. .

CLINICAL CANCER RESEARCH, 2015, 21 (21) :4774-4779

[46]

The significance of OX40 and OX40L to T-cell biology and immune disease [J].

Croft, Michael ;

So, Takanori ;

Duan, Wei ;

Soroosh, Pejman .

IMMUNOLOGICAL REVIEWS, 2009, 229 :173-191

[47]

Cuburu N., 2003, INT J CANCER, V142, P1467

[48]

Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide [J].

Currier, Mark A. ;

Gillespie, Rebecca A. ;

Sawtell, Nancy M. ;

Mahller, Yonatan Y. ;

Stroup, Greg ;

Collins, Margaret H. ;

Kambara, Hirokazu ;

Chiocca, E. Antonio ;

Cripe, Timothy P. .

MOLECULAR THERAPY, 2008, 16 (05) :879-885

[49]

Prime-boost vaccination with recombinant protein and adenovirus-vector expressing Plasmodium vivax circumsporozoite protein (CSP) partially protects mice against Pb/Pv sporozoite challenge [J].

de Camargo, Tarsila Mendes ;

de Freitas, Elisangela Oliveira ;

Gimenez, Alba Marina ;

Lima, Luciana Chagas ;

Caramico, Karina de Almeida ;

Francoso, Katia Sanches ;

Bruna-Romero, Oscar ;

Andolina, Chiara ;

Nosten, Francois ;

Renia, Laurent ;

Ertl, Hildegund C. J. ;

Nussenzweig, Ruth S. ;

Nussenzweig, Victor ;

Rodrigues, Mauricio M. ;

Reyes-Sandoval, Arturo ;

Soares, Irene S. .

SCIENTIFIC REPORTS, 2018, 8

[50]

Armed oncolytic viruses: A kick-start for anti-tumor immunity [J].

de Graaf, J. F. ;

de Vor, L. ;

Fouchier, R. A. M. ;

van den Hoogen, B. G. .

CYTOKINE & GROWTH FACTOR REVIEWS, 2018, 41 :28-39

← 1 2 3 4 5 6 7 8 9 10 →